BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27476618)

  • 1. Modulation of plasminogen activator inhibitor-1 (PAI-1) by the naphthoquinone shikonin.
    Han T; Zhang G; Yan D; Yang H; Ma T; Ye Z
    Fitoterapia; 2016 Sep; 113():117-22. PubMed ID: 27476618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase.
    Gong L; Proulle V; Fang C; Hong Z; Lin Z; Liu M; Xue G; Yuan C; Lin L; Furie B; Flaumenhaft R; Andreasen P; Furie B; Huang M
    J Cell Mol Med; 2016 Oct; 20(10):1851-60. PubMed ID: 27197780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-acting PAI-1 inhibitor reduces thrombus formation.
    Peng S; Xue G; Gong L; Fang C; Chen J; Yuan C; Chen Z; Yao L; Furie B; Huang M
    Thromb Haemost; 2017 Jun; 117(7):1338-1347. PubMed ID: 28405670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis.
    Humphries J; Gossage JA; Modarai B; Burnand KG; Sisson TH; Murdoch C; Smith A
    J Vasc Surg; 2009 Nov; 50(5):1127-34. PubMed ID: 19703758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a small molecule PAI-1 inhibitor, ZK4044.
    Liang A; Wu F; Tran K; Jones SW; Deng G; Ye B; Zhao Z; Snider RM; Dole WP; Morser J; Wu Q
    Thromb Res; 2005; 115(4):341-50. PubMed ID: 15668194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.
    Gupta KK; Donahue DL; Sandoval-Cooper MJ; Castellino FJ; Ploplis VA
    Sci Rep; 2017 Mar; 7(1):365. PubMed ID: 28336948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PAI-1: a new anti-thrombotic approach.
    Wu Q; Zhao Z
    Curr Drug Targets Cardiovasc Haematol Disord; 2002 Jun; 2(1):27-42. PubMed ID: 12769655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury].
    Kong LH; Ye YW; Zhou H; Zhou HJ; Du YJ; Cui CX
    Zhen Ci Yan Jiu; 2010 Dec; 35(6):409-14. PubMed ID: 21375013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis.
    Berry CN; Lunven C; Lechaire I; Girardot C; O'Connor SE
    Br J Pharmacol; 1998 Sep; 125(1):29-34. PubMed ID: 9776340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
    Baldwin JF; Sood V; Elfline MA; Luke CE; Dewyer NA; Diaz JA; Myers DD; Wakefield T; Henke PK
    J Vasc Surg; 2012 Oct; 56(4):1089-97. PubMed ID: 22796119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PAI-1 Activity by Toddalolactone as a Mechanism for Promoting Blood Circulation and Removing Stasis by Chinese Herb
    Yu B; Zhang G; Jin L; Zhang B; Yan D; Yang H; Ye Z; Ma T
    Front Pharmacol; 2017; 8():489. PubMed ID: 28785222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.
    Yatsenko T; Rios R; Nogueira T; Takahashi S; Tabe Y; Naito T; Takahashi K; Hattori K; Heissig B
    Front Immunol; 2023; 14():1299792. PubMed ID: 38313435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy.
    Crandall DL; Elokdah H; Di L; Hennan JK; Gorlatova NV; Lawrence DA
    J Thromb Haemost; 2004 Aug; 2(8):1422-8. PubMed ID: 15304050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis].
    Chen JM; Wang L; Liu T; Xing LJ; Zheng PY; Ji G
    Zhong Xi Yi Jie He Xue Bao; 2009 Jul; 7(7):642-50. PubMed ID: 19615318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
    Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.